Literature DB >> 3082762

Smooth lipopolysaccharide is the major protective antigen for mice in the surface extract from IATS serotype 6 contributing to the polyvalent Pseudomonas aeruginosa vaccine PEV.

S MacIntyre, R Lucken, P Owen.   

Abstract

The nature of the protective antigen in one of the sixteen monovalent extracts (viz., extract-6) contributing to the pseudomonas polyvalent extract vaccine (PEV) was studied in a mouse challenge assay. Selective removal, by filtration through Sep-Pak C18 cartridges, of two major protein antigens with molecular weights of 16,200 and 21,000 had no effect on the protection afforded by extract-6. When analyzed on the basis of 2-keto-3-deoxyoctonate, lipopolysaccharide (LPS) purified by hot phenol extraction (LPS-A) from Pseudomonas aeruginosa (International Antigenic Typing System serotype 6) could account in full for the protective capacity of extract-6. Comparative analysis of LPS heterogeneity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by silver staining indicated that both extract-6 and LPS-A possessed similar spectra of smooth LPS molecules, containing between 10 and approximately equal to 50 O-antigen repeating units. Differences in the profiles of heterogeneity displayed by LPS in LPS-A and extract-6 were restricted to molecular species with short O-antigen chains. Subfractionation of LPS molecules on the basis of number of O-antigen repeating units was achieved by gel filtration in the presence of deoxycholate. Protection experiments performed on the subfractionated species of LPS-A revealed a relationship between O-antigen chain length and protective capacity; molecules with over 18 O-antigen repeating units being 50 to 100 times more protective than those with zero-two repeating units. The results indicate that most of the protection afforded by LPS-A and extract-6 can be accounted for by LPS molecules possessing extended (10 or more) O-antigen repeating units.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082762      PMCID: PMC262200          DOI: 10.1128/iai.52.1.76-84.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.

Authors:  R J Jones
Journal:  J Hyg (Lond)       Date:  1979-06

2.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

3.  The succinate dehydrogenase of Escherichia coli. Immunochemical resolution and biophysical characterization of a 4-subunit enzyme complex.

Authors:  C Condon; R Cammack; D S Patil; P Owen
Journal:  J Biol Chem       Date:  1985-08-05       Impact factor: 5.157

4.  A new method for the extraction of R lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1969-06

5.  A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria.

Authors:  Y D Karkhanis; J Y Zeltner; J J Jackson; D J Carlo
Journal:  Anal Biochem       Date:  1978-04       Impact factor: 3.365

6.  Outer membrane of Pseudomonas aeruginosa: heat- 2-mercaptoethanol-modifiable proteins.

Authors:  R E Hancock; A M Carey
Journal:  J Bacteriol       Date:  1979-12       Impact factor: 3.490

7.  A new Pseudomonas vaccine: preliminary trial on human volunteers.

Authors:  R J Jones; E A Roe; E J Lowbury; J J Miler; J F Spilsbury
Journal:  J Hyg (Lond)       Date:  1976-06

8.  Phospholipid and lipopolysaccharide in Proteus mirabilis and its stable protoplast L-form. Difference in content and fatty acid composition.

Authors:  J Gmeiner; H H Martin
Journal:  Eur J Biochem       Date:  1976-08-16

9.  Further purification and characterization of high-molecular-weight polysaccharide from Pseudomonas aeruginosa.

Authors:  G B Pier; M Cohen; H Jennings
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

10.  A new polyvalent Pseudomonas vaccine.

Authors:  J M Miler; J F Spilsbury; R J Jones; E A Roe; E J Lowbury
Journal:  J Med Microbiol       Date:  1977-02       Impact factor: 2.472

View more
  17 in total

1.  Role of lipopolysaccharide and complement in susceptibility of Klebsiella pneumoniae to nonimmune serum.

Authors:  B Ciurana; J M Tomás
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

2.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

3.  Phage display and bacterial expression of a recombinant Fab specific for Pseudomonas aeruginosa serotype O6 lipopolysaccharide.

Authors:  N L Tout; J S Lam
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

4.  Molecular structures that influence the immunomodulatory properties of the lipid A and inner core region oligosaccharides of bacterial lipopolysaccharides.

Authors:  P J Baker; T Hraba; C E Taylor; P W Stashak; M B Fauntleroy; U Zähringer; K Takayama; T R Sievert; X Hronowski; R J Cotter
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

5.  Mouse interleukin-1 receptor antagonist induced by Actinobacillus actinomycetemcomitans lipopolysaccharide blocks the effects of interleukin-1 on bone resorption and osteoclast-like cell formation.

Authors:  T Nishihara; Y Ohsaki; N Ueda; N Saito; G R Mundy
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

6.  Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.

Authors:  H J Zweerink; M C Gammon; C F Hutchison; J J Jackson; D Lombardo; K M Miner; J M Puckett; T J Sewell; N H Sigal
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

7.  Nucleotide sequences of the genes regulating O-polysaccharide antigen chain length (rol) from Escherichia coli and Salmonella typhimurium: protein homology and functional complementation.

Authors:  R A Batchelor; P Alifano; E Biffali; S I Hull; R A Hull
Journal:  J Bacteriol       Date:  1992-08       Impact factor: 3.490

Review 8.  Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.

Authors:  Gerald B Pier
Journal:  Int J Med Microbiol       Date:  2007-04-27       Impact factor: 3.473

9.  Murine macrophage interleukin-1 release by capsularlike serotype-specific polysaccharide antigens of Actinobacillus actinomycetemcomitans.

Authors:  T Takahashi; T Nishihara; Y Ishihara; K Amano; N Shibuya; I Moro; T Koga
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

10.  A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Terashima; I Uezumi; T Tomio; M Kato; K Irie; T Okuda; S Yokota; H Noguchi
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.